You have no items in your shopping cart.
On Promotion
Elisa Kits Promotion 1
Products on Sale 0
Category
Antibodies 1178
Proteins and Peptides 1121
Small Molecules 284
Tools 65
Assays and Kits 42
Species Host
Rabbit 342
Mouse 234
Human 151
Goat 29
E. coli 28
Mammal 24
Plant 8
Camelus 6
Gallus 1
Tested Applications
ELISA 1023
WB 582
IF 82
IHC 55
NeA 52
Blocking 50
EIA 45
FC 45
Kinetics 33
IHC-P 20
IP 17
LF 13
SDS-PAGE 12
GICA 11
ICC 10
CLIA 8
MS 8
Functional Studies 7
IA 7
In vivo 6
Crystallography 5
Control 4
DOT 4
FA 2
Reactivity
Virus 778
Human 182
Other 54
Mouse 52
Rat 15
Hamster 3
Primate 2
All 1
Predicted Reactivity
Virus 82
Bovine 6
Canine 1
Equine 1
Guinea 1
Mouse 1
Pig 1
Rabbit 1
Rat 1
Zebrafish 1
Conjugation
Unconjugated 983
Biotin 61
HRP 54
AP 24
PE 16
FITC 15
APC 14
Cy3 14
iFluor647 14
AE 7
IRDye800 4
Clonality
Monoclonal 593
Polyclonal 402
Recombinant 173
Matched Antibody
Yes 0
No 2690
Featured Product
Yes 327
Has Publications
Yes 1
No 2689
Search results for: 'SARS-CoV-2'
98.00%
28.4 kDa (predicted); 35.88 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutations L452R, E484Q) (Arg319-Phe541) was expressed with a C-terminal polyhistidine tag followed by an AVI tag. The purified protein was biotinylated in vitro. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.617, B.1.617.1, B.1.617.3) which emerged in the India. Predicted N terminal: Arg 319
C-His-Avi
20 μg98.00%
77.95 kDa (predicted); 90.57 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1 (YP_009724390.1, with mutations (HV69-70, Y145)deletion, N501Y, A570D, D614G, P681H) (Met1-Arg685) was expressed with a C-terminal polyhistidine tag followed by an AVI tag. The purified protein was biotinylated in vitro. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.1.7) which emerged in the UK. Predicted N terminal: Val 16
C-His-Avi
20 μg98.00%
77.84 kDa (predicted); 120.35 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1 (YP_009724390.1, with mutations (LAL242-244)deletion, L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G) (Met1-Arg685) was expressed with a C-terminal polyhistidine tag followed by an AVI tag. The purified protein was biotinylated in vitro. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.351) which emerged in the South Africa. Predicted N terminal: Val 16
C-His-Avi
20 μg98.00%
78.43 kDa (predicted); 116 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1 (YP_009724390.1, with mutations T19R, G142D, L452R, E484Q, D614G, P681R) (Met1-Arg685) was expressed with a C-terminal polyhistidine tag followed by an AVI tag. The purified protein was biotinylated in vitro. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.617.3) which emerged in the India. Predicted N terminal: Val 16
C-His-Avi
20 μg98.00%
28.48 kDa (predicted); 36.17 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutation K417N, E484K, N501Y) (Arg319-Phe541) was expressed with a C-terminal polyhistidine tag followed by an AVI tag. The purified protein was biotinylated in vitro. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.351) which emerged in the South Africa. Predicted N terminal: Ser
C-His-Avi
20 μg98.00%
51.89 kDa (predicted); 58.07 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutation L452R, T478K) (Arg319-Phe541) was expressed with the Fc region of human IgG1 at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.617.2) which emerged in the India. Predicted N terminal: Arg 319
C-Fc
100 μg98.00%
51.94 kDa (predicted); 56.01 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutation K417N, E484K, N501Y) (Arg319-Phe541) was expressed with the Fc region of human IgG1 at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.351) which emerged in the South Africa. Predicted N terminal: Ser
C-Fc
100 μg98.00%
76.27 kDa (predicted); 95.12 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1 (YP_009724390.1, with mutations T19R, G142D, E156G, 157-158 deletion, L452R, T478K, D614G, P681R) (Met1-Arg685) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.617.2) which emerged in the India. Predicted N terminal: Val 16
C-His
100 μg98.00%
76.58 kDa (predicted); 106.41 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1 (YP_009724390.1, with mutations T95I, G142D, E154K, L452R, E484Q, D614G, P681R) (Met1-Arg685) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.617.1) which emerged in the India. Predicted N terminal: Val 16
C-His
100 μg98.00%
76.4 kDa (predicted); 114.7 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1 (YP_009724390.1) (Met1-Arg685, with mutations K417N, E484K, N501Y, D614G) was expressed with a polyhistidine tag at the C-terminus. The purified protein was biotinylated in vitro. The mutations were identified in the SARS-CoV-2 variant (known as 20C/501Y.V2 or B.1.351 lineage) which emerged in South Africa. Predicted N terminal: Val 16
C-His
20 μg